Cargando…

Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease

Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Jie, Cui, Yanhua, Li, Song, Le, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876590/
https://www.ncbi.nlm.nih.gov/pubmed/26585523
http://dx.doi.org/10.2174/1570159X14666151120123025
_version_ 1782433261395378176
author Dong, Jie
Cui, Yanhua
Li, Song
Le, Weidong
author_facet Dong, Jie
Cui, Yanhua
Li, Song
Le, Weidong
author_sort Dong, Jie
collection PubMed
description Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, anticholinergics and other newly developed non-DAergic drugs can make a better control of motor symptoms or alleviate levodopa-induced motor complications. Moreover, non-motor symptoms of PD, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances caused by intrinsic PD pathology or drug-induced side effects, are gaining increasing attention and urgently need to be taken care of due to their impact on quality of life. Currently, neuroprotective therapies have been investigated extensively in pre-clinical studies, and some of them have been subjected to clinical trials. Furthermore, non-pharmaceutical treatments, including deep brain stimulation (DBS), gene therapy, cell replacement therapy and some complementary managements, such as Tai chi, Yoga, traditional herbs and molecular targeted therapies have also been considered as effective alternative therapies to classical pharmaceutics. This review will provide us updated information regarding the current drugs and non-drugs therapies for PD.
format Online
Article
Text
id pubmed-4876590
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-48765902016-11-01 Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease Dong, Jie Cui, Yanhua Li, Song Le, Weidong Curr Neuropharmacol Article Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs have been considered as the main therapy against motor symptoms of Parkinson's disease (PD). It is proposed that DAergic drugs in combination with other medications, such as monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, anticholinergics and other newly developed non-DAergic drugs can make a better control of motor symptoms or alleviate levodopa-induced motor complications. Moreover, non-motor symptoms of PD, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances caused by intrinsic PD pathology or drug-induced side effects, are gaining increasing attention and urgently need to be taken care of due to their impact on quality of life. Currently, neuroprotective therapies have been investigated extensively in pre-clinical studies, and some of them have been subjected to clinical trials. Furthermore, non-pharmaceutical treatments, including deep brain stimulation (DBS), gene therapy, cell replacement therapy and some complementary managements, such as Tai chi, Yoga, traditional herbs and molecular targeted therapies have also been considered as effective alternative therapies to classical pharmaceutics. This review will provide us updated information regarding the current drugs and non-drugs therapies for PD. Bentham Science Publishers 2016-05 2016-05 /pmc/articles/PMC4876590/ /pubmed/26585523 http://dx.doi.org/10.2174/1570159X14666151120123025 Text en ©2016 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Dong, Jie
Cui, Yanhua
Li, Song
Le, Weidong
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
title Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
title_full Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
title_fullStr Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
title_full_unstemmed Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
title_short Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
title_sort current pharmaceutical treatments and alternative therapies of parkinson's disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876590/
https://www.ncbi.nlm.nih.gov/pubmed/26585523
http://dx.doi.org/10.2174/1570159X14666151120123025
work_keys_str_mv AT dongjie currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease
AT cuiyanhua currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease
AT lisong currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease
AT leweidong currentpharmaceuticaltreatmentsandalternativetherapiesofparkinsonsdisease